Previous 10 | Next 10 |
home / stock / onc:cc / onc:cc news
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the w...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
2024-05-24 08:45:04 ET Palm Beach, FL – May 24, 2024 – The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of ca...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action PR Newswire Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's a...
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial PR Newswire Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy uti...
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- met...
2024-05-09 12:15:23 ET Palm Beach, FL – May 9, 2024 – FN Media Group News Commentary – The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 American...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer PR Newswire US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study ...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference Canada NewsWire SAN DIEGO and CALGARY, AB , May 8, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading cl...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...